Genitrope

, a Redwood City, Calif., biotechnology company, has filed an initial public offering registration statement with the

Securities and Exchange Commission

seeking to raise $68.8 million.

TST Recommends

The company's filing on Aug. 6 doesn't disclose the timetable for the offering, the number of shares to be offered or the price of the shares. The underwriters are WR Hambrecht & Co., of San Francisco, and Punk Ziegel & Co., of New York.

Genitrope, which has no commercial products or revenue, is trying to develop cancer therapies that utilize the body's immune system to fight diseases.

The company is focusing on non-Hodgkin's lymphoma -- for which its MyVax drug is being tested in a Phase III trial -- and leukemia. A Phase III clinical trial is the final test before a company submits its drug application to the Food and Drug Administration.